Pharmacogenetics of Antidepressant-Induced Disinhibition
Recruiting now NCT03953014
Run by University of Calgary · for 6 to 17 · All sexes
What this study is about
The purpose of this study is to identify pharmacogenetic profiles associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioral disinhibition in children with Major depressive disorder (MDD), anxiety disorders and/or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.
Who can join (things the study team will check)
✅ You may be able to join if…
- Aged 6 - 24 years
- Medical records available
- Diagnosis of MDD, anxiety disorder, or OCD
- Current or past history of SSRI therapy
🚫 You may not be able to join if…
- Inability of parent/legal guardian to give informed consent
- Inability of the child to give informed assent
- Unwillingness of child to provide saliva sample for genetic analysis
- Current, past or suspected diagnosis of attention deficit hyperactivity disorder, oppositional defiant disorder, conduct disorder, bipolar disorder, psychotic disorder, or pervasive developmental disorder.
Where this trial is running
- Child and Adolescent Addiction, Mental Health & Psychiatry, Calgary, Alberta, Canada
Who to contact
Madison Heintz, MSW · 5875739747 · psychpgxlab@ucalgary.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT03953014.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.